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 The PDE6brd1 (rd1) mouse is a model of rapid retinal
degeneration [1]. It results from a point mutation in the gene
encoding the β-subunit of rod photoreceptor cGMP-phosphodi-
esterase (β-PDE), leading to a stop codon (Tyr347Ter), trun-
cated protein, and nonsense-mediated mRNA decay [2]. In
the rd1 mouse, rod photoreceptor loss is nearly complete by
postnatal day (PN) 21 [3,4]. Mutations in the same gene are
responsible for retinal degeneration in patients with retinitis
pigmentosa [5,6].
Targeted gene repair aims to correct mutations in genomic
DNA by using RNA/DNA oligonucleotides (RDOs) or single-
stranded DNA oligonucleotides (ssODNs) [7,8]. This gene
therapy strategy should allow for a permanent correction of
the genomic DNA and for normal physiologic regulation of
the corrected gene by its endogenous promoter [7,8]. Targeted
gene repair has been effective in inducing genotypic and phe-
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Purpose: The aim of this study was to test whether oligonucleotide-targeted gene repair can correct the point mutation in
genomic DNA of PDE6brd1 (rd1) mouse retinas in vivo.
Methods: Oligonucleotides (ODNs) of 25 nucleotide length and complementary to genomic sequence subsuming the rd1
point mutation in the gene encoding the β-subunit of rod photoreceptor cGMP-phosphodiesterase (β-PDE), were synthe-
sized with a wild type nucleotide base at the rd1 point mutation position. Control ODNs contained the same nucleotide
bases as the wild type ODNs but with varying degrees of sequence mismatch. We previously developed a repeatable and
relatively non-invasive technique to enhance ODN delivery to photoreceptor nuclei using transpalpebral iontophoresis
prior to intravitreal ODN injection. Three such treatments were performed on C3H/henJ (rd1) mouse pups before postna-
tal day (PN) 9. Treatment outcomes were evaluated at PN28 or PN33, when retinal degeneration was nearly complete in
the untreated rd1 mice. The effect of treatment on photoreceptor survival was evaluated by counting the number of nuclei
of photoreceptor cells and by assessing rhodopsin immunohistochemistry on flat-mount retinas and sections. Gene repair
in the retina was quantified by allele-specific real time PCR and by detection of β-PDE-immunoreactive photoreceptors.
Confirmatory experiments were conducted using independent rd1 colonies in separate laboratories. These experiments
had an additional negative control ODN that contained the rd1 mutant nucleotide base at the rd1 point mutation site such
that the sole difference between treatment with wild type and control ODN was the single base at the rd1 point mutation
site.
Results: Iontophoresis enhanced the penetration of intravitreally injected ODNs in all retinal layers. Using this delivery
technique, significant survival of photoreceptors was observed in retinas from eyes treated with wild type ODNs but not
control ODNs as demonstrated by cell counting and rhodopsin immunoreactivity at PN28. β-PDE immunoreactivity was
present in retinas from eyes treated with wild type ODN but not from those treated with control ODNs. Gene correction
demonstrated by allele-specific real time PCR and by counts of β-PDE-immunoreactive cells was estimated at 0.2%.
Independent confirmatory experiments showed that retinas from eyes treated with wild type ODN contained many more
rhodopsin immunoreactive cells compared to retinas treated with control (rd1 sequence) ODN, even when harvested at
PN33.
Conclusions: Short ODNs can be delivered with repeatable efficiency to mouse photoreceptor cells in vivo using a
combination of intravitreal injection and iontophoresis. Delivery of therapeutic ODNs to rd1 mouse eyes resulted in
genomic DNA conversion from mutant to wild type sequence, low but observable β-PDE immunoreactivity, and preser-
vation of rhodopsin immunopositive cells in the outer nuclear layer, suggesting that ODN-directed gene repair occurred
and preserved rod photoreceptor cells. Effects were not seen in eyes treated with buffer or with ODNs having the rd1
mutant sequence, a definitive control for this therapeutic approach. Importantly, critical experiments were confirmed in
two laboratories by several different researchers using independent mouse colonies and ODN preparations from separate
sources. These findings suggest that targeted gene repair can be achieved in the retina following enhanced ODN delivery.
Correspondence to: Dr. Francine Behar-Cohen, INSERM U598, 15
rue de l’Ecole de Médecine 75270 Paris Cedex 06; Phone: 331 40 46
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notypic corrections both in vitro and in several animal models
of various disorders such as hemophilia, Crigler-Najjar syn-
drome type 1, albinism, Duchenne muscular dystrophy, hy-
perlipidemia type 2, and sickle cell disease [9-22]. The major-
ity of in vivo studies have used RDOs. Recently, successful
repair has been described in vivo with phosphorothioate single-
stranded ssODNs [23-25]. Compared to RDOs, ssODNs
present advantages: (1) Their synthesis is more efficient, with
higher yields and purity; (2) they are less expensive; and (3)
they are more stable. Moreover, the induced repair is more
reproducible [26]. Reproducibility is one of the major limita-
tions of gene repair using RDOs, so enhanced reproducibility
with ssODNs is of considerable importance [27].
Efficient DNA delivery to photoreceptor nuclei is requi-
site for targeted gene repair to occur [28,29]. Within the living
eye, effective gene therapy relies on high transfection effi-
ciency of the cells of interest [30]. Subretinal or intravitreal
injection does not ensure efficient transfection of photorecep-
tor cells. We recently demonstrated that the rd1 mutation can
be corrected in vitro by gene repair in non-ocular cell lines
using locked nucleic acids (LNAs) and phosphorothioate
ODNs designed to correct the point mutation in the β-PDE
gene [25]. To translate these results to the rd1 mouse in vivo,
we evaluated the effect of current to enhance the delivery of
ODNs to photoreceptors [29]. Low current density iontophore-
sis indeed safely promotes intraocular penetration of drugs
[31-34] and gene fragments [35-37]. We also previously ob-
served that iontophoresis enhances the intracellular penetra-
tion of intact ODNs in corneal cells [35]. Preliminary in vivo
findings using this iontophoresis procedure to deliver
phosphorothioate ODN and LNA ODNs in the rd1 mouse
retina have shown beneficial effects on photoreceptors sur-
vival [25].
In the work reported here, we evaluated whether ionto-
phoresis performed immediately before the intravitreal injec-
tion of ODNs enhanced their localization into mouse photore-
ceptor nuclei and resulted in gene repair and altered pheno-
type. We report that delivery of specific phosphorothioate
ODNs designed to correct the point mutation in the β-PDE
gene, using iontophoresis coupled to intravitreal injection of
ODNs, induced genotypic and phenotypic changes of the rd1
retina. Conversion of the mutant nucleotide to wild type in
this model is associated with appearance of β-PDE immunore-
activity in retinal cells, partial preservation of rhodopsin im-
munoreactive cells in the outer nuclear layer (ONL), and in-
creased photoreceptor cell counts. Our genotypic and pheno-
typic data show that, though modest, targeted gene repair was
achieved in vivo in the rd1 mouse neural retina.
METHODS
Animals:  C3H/HenJ mice homozygous for the nonsense mu-
tation (amino acid position 347) in the β-PDE gene were used.
Wild type mice (C57BL6 or 129sv) served as positive con-
trols. Mice were obtained from Janvier (Le Genest, France)
and The Jackson Laboratory (Bar Harbor, Maine). Mice were
maintained in clear plastic cages and subjected to a standard
12h:12h light-dark cycle. Experiments were conducted in ac-
cordance with the ARVO Statement for the Use of Animals in
Ophthalmologic and Vision Research and the institutional
guidelines regarding animal experimentation in Ophthalmic
and Vision Research.
Oligonucleotides:  ODNs of 25-nucleotide length and with
sequence subsuming the rd1 point mutation were synthesized
and purified by high pressure liquid chromatography (Proligo,
Paris, France). ODNs were synthesized with six
phosphorothioate linkages at 5' and 3' ends (Table 1). ODNs
in distilled water were quantified by absorbance at 260 nm.
The sense (S) and antisense (AS) wild type (WT) alleles of
the β-PDE gene sequence were synthesized (WTS and WTAS,
respectively; see Table 1 for nomenclature and sequences).
Other ODNs were synthesized with the same bases as WTS,
but with some or all out of order (e.g., containing mismatches
to the genomic sequence). The central seven bases of WTSscr7
and all 25 bases of WTSscr25 were scrambled (Table 1). These
ODNs were not expected to induce gene repair and were thus
used as negative controls. One preparation of WTS was 5' la-
beled with CY3 for use in localization studies.
Iontophoresis and injection:  A transpalpebral (across eye-
lids) iontophoresis system was used (patent number
FR2830766). We have found that applying transpalpebral ion-
tophoresis immediately after or before intravitreal injection
of ODNs leads to the same penetration efficiencies [38]. There-
fore, we chose to perform iontophoresis immediately prior to
the intravitreal injection of ODNs in order to avoid manipula-
tion of the injected pups’ eyes and reduce the potential danger
of secondary infection.
Prior to iontophoresis, pups’ eyelids were opened with a
scalpel (Swann Morton, Peynier, France) if needed and tetra-
caine 1% drops (Novartis Ophthalmics SA, Rueil Malmaison,
France) were instilled. An hour-glass-shaped aluminum foil
and disposable medical grade hydrophilic polyurethane sponge
(3.2 mm thick, 1.5x0.7 cm length by width; Optis, Levallois,
France), was soaked in phosphate buffered saline (PBS: 0.2 g/
l KCl, 0.2 g/l KH2PO4, 8 g/l NaCl, 2.16 g/l Na2HPO4 7H2O,
pH 7.4) and used as the active negative electrode (Figure 1A).
The electrode covered both eyelids and was connected to the
generator with the clip shown at the top of Figure 1C. The
return electrode was connected to the tail and hind foot pads
of the mouse. Anionic iontophoresis (negative electrode con-
nected to the eyelids) was performed with a 1.5 mA current
for 5 min (1.43 mA/cm2; Figure 1B). An audio-visual alarm
indicated any disruption of the electric circuit ensuring a con-
trolled delivery of the current.
Intraocular injections were carried out with borosilicate
micropipette needles (Phymep, Paris, France) pulled with a
pipette puller (model 720, Kopf Instruments,Tujunga, Cali-
fornia) and cut at 2 mm from the neck, leading to a 60 µm
injection outer diameter. Micropipette needles were linked to
an Eppendorf microinjector 5242 (Roucaire, Velizy, France).
1 µl of PBS or ODN (concentrations are given in the next
section) was injected into the vitreous. The position of the
needle was monitored by observation under a dissecting mi-
croscope through a glass cover slip placed on the corneal sur-
face. To limit loss of the injected solution and allow the in-
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traocular pressure to equilibrate (as observed by the return of
normal iris perfusion), the micropipette needle was left in place
for 10 s before withdrawal.
For tissue harvest, mice were sacrificed by a lethal dose
of pentobarbital (6 g/100 ml; Ceva Santé Animale, Libourne,
France) injected intraperitoneally.
Localization of oligonucleotides:  Eight eyes of rd1 mice
at PN7 underwent a single transpalpebral iontophoresis (an-
ionic, 5 min, 1.5 mA) followed by an intravitreal injection of
1 µl of CY3-labeled WTS ODN (1 µl of 272 µM). For the
control groups, rd1 mice at PN7 received either iontophoresis
followed by PBS injection, ODN injection without iontophore-
sis, iontophoresis without injection, or had no treatment (8
eyes for each condition). Animals were sacrificed 1 h after
treatment. The eyes were enucleated, rinsed in PBS, and em-
bedded with Tissue-Tek OCT-compound (Bayer Diagnostics,
Puteaux, France) for cryo-sectioning. Sections (10 µm) were
fixed in 4% paraformaldehyde (Merck Eurolab, Strasbourg,
France) for 5 min at room temperature, washed in PBS,
counter-stained for 2 min with DAPI (4',6-diamino-2-
phenylindole; 1/3000 dilution; Sigma-Aldrich, Saint-Quentin
Fallavier, France), washed in PBS, mounted in Gel Mount
(Microm Microtech, Francheville, France) and examined un-
der a fluorescence microscope (Aristoplan, Leica, Rueil
Malmaison, France) with HBO103w lamp and a digital SPOT
camera (Optilas, Evry, France). For each eye, sections at the
optic nerve level were counter-stained with hematoxylin and
eosin (H&E) for structural analysis.
Outer nuclear layer cell counting:  Eyes of PN28 mice
were enucleated, quickly frozen in Tissue-Tek OCT-compound
(Bayer Diagnostics), and sectioned (10 mm). For each eye, 5
sections that included optic nerve were H&E stained. For each
section, the number of nuclei in the ONL was counted in the
same region at 400 mm from each edge of the optic nerve
over a 400 mm length (n=10 values for each eye). Each sec-
tion was counted by at least two observers. Observers did not
know which experimental group sections were from (i.e.,
counts were conducted in a double-blind manner).
Rhodopsin immunohistochemistry on whole flat-mount
retinas:  Rhodopsin immunohistochemistry was assessed on
whole flat-mount retinas as previously described [39]. Briefly,
at PN19 and 28, ocular globes were fixed in 4% paraformal-
dehyde (Merck Eurolab) for 1 h. Retinas were isolated, placed
in PBS in 1.5 ml microcentrifuge tubes, permeabilized in PBS,
0.1% Triton X-100 (Sigma-Aldrich) for 5 min, and incubated
in blocking buffer (PBS containing 0.1% bovine serum albu-
min, 0.1% Tween 20 and 0.1% sodium azide; all chemicals
from Sigma-Aldrich) for 15 min. Retinas were incubated for
one hour with the rhodopsin-specific mouse monoclonal anti-
body, rho-4D2 (1/100 dilution in blocking buffer; kindly pro-
vided by Dr. Robert Molday, University of British Columbia,
Vancouver BC, Canada [40]). As negative controls, normal
mouse serum (Nordic Immunological Laboratories, Tebu-bio,
Le Perray en Yvelines, France) or mouse monoclonal anti-
body Leu-M5 directed against macrophages and monocytes
(BD Biosciences, Pont-de-Claix, France) were used instead
of rho-4D2 antibody (1/100 dilution in blocking buffer, 1 h).
Then, the retinas were washed three times for 5 min in block-
ing buffer and incubated with a secondary goat anti-IgG mouse
antibody conjugated to Alexa Fluor 488 (1/250 dilution in
blocking buffer; Molecular Probes, Leiden, the Netherlands).
The incubation volumes were 0.2 ml for antibody incubations
and 1.5 ml for blocking and washing steps. After washing three
times in PBS for 5 min, retinas were mounted in PBS-glyc-
erol (1/1), with the photoreceptor layer facing up, and exam-
ined by fluorescence microscopy with a 2.5X objective and
photographed using a digital SPOT camera (Optilas). All pic-
tures were taken with an exposure time of 5 s. For each retina,
three pictures were taken to cover the whole retinal surface.
Photographs of flat-mounts were merged in Photoshop 7.0
(Adobe Systems Inc., San Jose, California) to reconstruct the
whole retina.
Intensity of rhodopsin immunoreactivity was quantified
by using the luminosity feature of Photoshop for raw pictures.
Tissue and background regions were manually selected. Any
residual pigmented epithelium was excluded. Mean pixel
brightness was determined for each region by using the “His-
togram” imaging feature. To normalize background levels
among images, the mean brightness level per pixel of the tis-
sue region was divided by the background region from each
flat-mount image.
Experiments with the WTS ODN, the corresponding two
negative control ODNs (WTSscr7 and WTSscr25), and the
untreated or PBS-treated controls were repeated three more
times (six eyes for each condition, three additional, replicated
experiments). Other controls included injection of the WTS
ODN without iontophoresis and iontophoresis without any in-
jection (4 eyes for each condition).
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TABLE 1. SEQUENCE OF THE OLIGONUCLEOTIDES TESTED FOR IN VIVO
GENE REPAIR
ODN name                 Sequence
--------   -------------------------------------
WTS        C*C*T*T*C*C*AACCTACGTAGCA*G*A*A*A*G*T
WTAS       A*C*T*T*T*C*TGCTACGTAGGTT*G*G*A*A*G*G
WTSscr7    C*C*T*T*C*C*AACAACGTCTGCA*G*A*A*A*G*T
WTSscr25   A*A*T*C*A*C*AGTTGCCTATAGG*A*C*C*C*C*A
rd1S       C*C*T*T*C*C*AACCTAAGTAGCA*G*A*A*A*G*T
These oligonucleotides (ODNs) were used in the gene repair experi-
ments detailed in the text. Sequences are presented 5' to 3', left to
right. “WTS” is wild type sense sequence and “WTAS” is wild type
antisense sequence. Treatment with these two ODNs is hypothesized
to lead to conversion of the rd1 mutation to wild type in genomic
DNA. “WTSscr7” is wild type sense sequence at the 5' and 3' ends,
but the middle seven bases, though the same as those in wild type,
are out of order, or scrambled (i.e., containing mismatches to the
genomic sequence). “WTSscr25” contains the same bases as WTS
but with all bases out of order compared to wild type sequence. “rd1S”
is rd1 sense sequence. That is, it contains the rd1 point mutation, an
adenine, rather than the wild type cytosine, at the 13th position, but is
otherwise identical to WTS. The last three ODNs should not be able
to induce genomic base conversion. Asterisk (*) represents
phoshphorothiate linkages, which were used to prevent nuclease deg-
radation.
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The effect of the number of treatments on response was
assessed by injecting WTS ODN (1 µl of 500 µM) following
iontophoresis at PN4 (one injection total), at PN4 and PN6
(two injections total), at PN4, 6, and 8 (three injections total),
or at PN6, PN8 and PN10 (three injections total). Each condi-
tion was tested on four eyes.
Rhodopsin immunohistochemistry on PN28 eye sections:
Eyes of PN28 PBS-treated (six eyes) or ODN-treated (eight
eyes) rd1 mice and untreated wild type (four eyes) were enucle-
ated, quickly frozen in Tissue-Tek OCT-compound (Bayer
Diagnostics), and sectioned (10 mm). For each eye, sections
that included optic nerve were H&E stained with for struc-
tural analysis. Sections were fixed in 4% paraformaldehyde
(Merck Eurolab) for 5 min at room temperature, washed in
PBS, and incubated 1 h in mouse rho-4D2 antibody (1/100
dilution in PBS). As negative controls, normal mouse serum
(Nordic Immunological Laboratories) or mouse monoclonal
antibody Leu-M5 (BD Biosciences) replaced the primary an-
tibodies (1/100 dilution in PBS). Slides were washed three
times in PBS and incubated with mouse anti-IgG conjugated
to Alexa Fluor 488 (1/250 dilution in PBS; Molecular Probes).
Then, the slides were washed three times in PBS, mounted in
PBS/glycerol (1/1) and examined under a fluorescence mi-
croscope (Leica).
β-phosphodiesterase immunohistochemistry on eye sec-
tions:  The presence of β-PDE immunoreactivity was assessed
in eye sections from PN28 untreated and PBS- or ODN-treated
rd1 mice previously labeled with rho-4D2. Immunohistochem-
istry was performed with rabbit IgG PDE6b antibody (1/100
dilution; Affinity Bioreagents, Golden, Colorado) or non-im-
mune rabbit serum (1/100 dilution) as primary antibodies and
goat anti-IgG rabbit antibody conjugated to Texas Red Fluor
(1/100 dilution; Molecular Probes) as secondary antibody.
Sections were mounted in PBS/glycerol (1/1) and examined
under a fluorescence microscope (Leica). Primary and sec-
ondary antibody concentrations and incubation times were
optimized such that background signal was undetectable in
untreated rd1 retina sections or when normal serum was sub-
stituted for primary antibody [41] (see Results section). The
specificity and selectivity of the primary antibody was dem-
onstrated by the observations that (1) only photoreceptor cells
showed immunoreactivity in wild type retina sections and (2)
only protein extracts from wild type retinas, but not rd1 reti-
nas, showed immunoreactivity with bands of correct size in
an immunoblot ([41] and Results section).
Genotypic changes induced in rd1 retinas treated with WTS:
Genomic DNA from rd1 retinas of mice treated with WTS
was extracted from individual whole flat-mount retinas (PN28)
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Figure 1. Iontophoresis device and eye sections from PN7 rd1 mice, 1 h after treatment.  Iontophoresis device. A: An eye-glass-shaped
electrode was made with aluminum foil and single-use disposable medical grade hydrophilic polyurethane sponge. B: The electrode covered
both closed eyelids of the treated newborn mouse iontophoresis. C: shows the generator and the return electrode. Eye section 1 h after
transpalpebral iontophoresis. D: Hematoxylin and eosin stained eye section showing integrity of the eye structures after iontophoresis Inset
shows tissue at high magnification. Eye sections 1 h after intravitreal injection of CY3-tagged oligonucleotide. In E-G, nuclei were stained
blue with DAPI and red with CY3. E: without prior iontophoresis, F: with prior iontophoresis (inset: high magnification of the ONL). G:
Control retina from an rd1 mouse injected with 1 µl of PBS with prior iontophoresis. The following abbreviations were used: outer nuclear
layer (ONL), inner nuclear layer (INL), and ganglion cell layer (GCL). Scale bars: A, B, C, 1 cm; D 1 mm; E, F, G and inset D, 100 µm; inset
F, 5 µm.
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using a DNeasy Tissue kit and eluted in 200 µl of AE buffer as
per manufacturer’s instructions (Qiagen, Courtaboeuf, France
and Valencia, California). Genomic DNA from wild type reti-
nas, untreated, and PBS-treated rd1 retinas served as controls.
Allele-specific real-time PCR was used to detect small
amounts of wild type sequence resulting from ODN treatment.
DNA samples isolated from treated and untreated retinas were
used as template DNA in PCR reactions with primers designed
to preferentially amplify wild type rather than mutant β-PDE
sequence. The 3' base of one primer was complementary to
wild type sequence, but not rd1 sequence, at position 1048 of
GenBank accession number X60133 [42]. Primers used for
preferential amplification of wild type β-PDE sequence were
5'-TGC AAG CAT TCA TTC CTT CGA C-3' and 5'-AAG
CCA CTT TCT GCT ACG-3'. For normalization calculations,
parallel reactions using aliquots of the same source of tem-
plate DNA were run using primers designed to amplify both
wild type and rd1 mutant β-PDE sequences (W149 and W150
of reference [4]): 5'-CAT CCC ACC TGA GCT CAC AGA
AAG-3' and 5'-GCC TAC AAC AGA GGA GCT TCT AGC-
3'. Reactions were run in a Bio-Rad iCycler iQ real time PCR
detection system with melt curve analysis (Bio-Rad, Hercules,
CA). Reactions of 20 µl final volume included template DNA
(10 ng), primers (50 nM), and QuantiTect SYBR Green PCR
Master Mix (Qiagen, Valencia, CA), which is composed of
SYBR Green I (a dye that fluoresces strongly when bound to
dsDNA), HotStarTaq DNA polymerase, dNTPs, and buffer
components optimized by the manufacturer. Poly (dI:dC), 20
ng per assay, was added to reduce nonspecific PCR products.
The limit of detection for quantification was considered
10 times the root mean square noise of fluorescence intensity
across a window usually spanning cycles 2 through 10. The
cycle number at which product accumulated past this detec-
tion threshold (Ct) was related to beginning copy number of a
specific template allele in a reaction by a calibration curve
created with standard amounts of the wild type β-PDE gene.
A lower Ct compared to untreated rd1 controls indicates the
presence of a specific allele, in this case, a presumed rd1 al-
lele repaired to wild type sequence (mutant adenine converted
to wild type cytosine). For each template DNA, the Ct from
either mutant or wild type allele specific β-PDE reactions were
subtracted from Ct of a non-allele specific reaction to correct
for differences in total DNA starting concentrations. Normal-
izing reactions were identical to β-PDE reactions with the
exception that PCR primers specific to the 18S-RNA gene were
used to amplify template DNA. Ct data are means±SEM of 5-
6 experimental samples assayed in 5-10 replicates. The effi-
ciency of the assay was determined by making calibration
curves of gene copy versus threshold cycle were made using
increasing amounts of wild type genomic DNA (1 pg to 10
ng) mixed with 10 ng of rd1 genomic DNA.
In separate control assays, various repair ODNs that con-
tained wild type sequence were added into DNA template
samples at several concentrations to determine whether their
presence caused artificial decreases or increases in Cts. Their
presence had no effect on Cts (data not shown) over a wide
range of concentrations.
Statistical analysis:  Unless otherwise noted, results were
expressed as means±SD and compared using the non-para-
metric Mann-Whitney test and analysis of variance (ANOVA)
with post-hoc Student-Newman-Keuls test. p<0.05 was con-
sidered as significant.
Confirmation of phenotypic changes following oligonucle-
otide treatment:  Confirmatory experiments were conducted
independently in collaborators’ laboratories using the meth-
odology described above and previously published [38] with
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Figure 2. Eye sections of treated and control PN28 rd1 mice and
outer nuclear layer cell counting.  Hematoxylin and eosin stained
sections of rd1 eyes showed an increased number of nuclei rows in
the outer nuclear layer (ONL) of oligonucleotide (ODN)-treated eyes.
A: Untreated mouse. B: PBS-treated mouse. C: Mouse treated with
WTAS ODN (corresponding to wild type antisense sequence). D:
Mouse treated with WTS ODN (corresponding to wild type sense
sequence). E: Counting of nuclei in the ONL shows a significant
increase of nuclei in WTAS ODN- and WTS ODN-treated eyes com-
pared to PBS-treated and untreated eyes (*p<0.05). Scale bars are A,
B, C, and D, 100 µm.
696
©2007 Molecular VisionMolecular Vision 2007; 13:692-706 <http://www.molvis.org/molvis/v13/a75/>
Figure 3. Treatment with WTS preserves rhodopsin at PN28.  Rhodopsin immunohistochemistry on wild type eye sections and rd1 whole flat-
mount retinas, reflecting the time course of the retinal degeneration and the treatment efficacy. A: Wild type eye section from a mouse at PN28.
B: Control eye section from wild type mouse at PN28 using normal mouse serum. C: rd1 flat-mount retina from a mouse at PN19 (inset: high
magnification). D: Control flat-mount retina from rd1 mouse at PN19 using normal mouse serum. E: rd1 flat-mount retina from a mouse at
PN28. F: PN28 rd1 flat-mount retina injected by WTS with prior iontophoresis at PN4, PN6, and PN8. G: PN28 rd1 flat-mount retina injected
by WTS without prior iontophoresis at PN4, PN6, and PN8. H: PN28 rd1 flat-mount retina iontophoresed without oligonucleotide injection at
PN4, PN6, and PN8. I: PN28 rd1 flat-mount retina injected with WTSscr7 with prior iontophoresis at PN4, PN6, and PN8. Scale bars are A and
B, 100 µm; C, D, E, F, G, H, and I, 1 mm; inset, 10 µm.
a few exceptions. Mice for experiments were bred from C3H/
henJ mice obtained from The Jackson Laboratory (Bar Har-
bor, ME, USA) and genotyped to confirm the homozygous
presence of the rd1 point mutation using the strategy of Pittler
and Baehr [4] (data not shown). Pups were treated with either
WTS or rd1S ODNs (Table 1) that were synthesized and puri-
fied by the Emory University Microchemical Facility (Atlanta,
Georgia). Littermates were always used and both ODNs were
always tested preclude handling or rearing confounds. In some
experiments, both eyes of a mouse received either WTS or
rd1S. In other experiments, each mouse received WTS in one
eye and rd1S in the other eye.
ODNs were delivered as described above with the excep-
tion that eyelids were always slit open prior to iontophoresis.
The local anesthetic used was 0.5% proparacaine (Akorn Inc.,
Buffalo Grove, Illinois), the polyurethane foam was 1.6 to 3.2
mm thick (Rynel, Wiscasset, Maine), and 0.5 µl of a 500 µM
ODN solution was intravitreally injected. Following each of
the three treatments, Refresh Tears (Allergan, Inc.; Irvine, CA,
USA) and Tribiotic Ointment (Taro Pharmaceuticals,
Bramalea, Ontario, Canada) were applied to eyes and eyelids.
Treated pups were sacrificed at PN33 by carbon dioxide
inhalation. Eyes were harvested and prepared for immunohis-
tology substantially as previously published [43]. Eyes were
marked on the superior limbus with indelible ink while still in
the socket for orientation. They were removed with forceps,
then injected at the ink mark with approximately 1 µl of 10%
buffered formalin (Stephens Scientific, Riverdale, New Jer-
sey). Eyes were soaked in formalin for 30 min, rinsed in PBS,
then stored in PBS in microcentrifuge tubes at 4 °C awaiting
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TABLE 2. QUANTIFICATION OF RHODOPSIN IMMUNOSTAINING ON
UNTREATED AND TREATED RD1 FLAT-MOUNT RETINAS
                                                  Number
                                      Standard      of
   Treatment      Tissue Fl/Bkgd Fl   deviation   retinas
---------------   -----------------   ---------   -------
None                   1.36            0.09          6
PBS                    1.71            0.17          6
WTS                    2.57*           0.44          6
WTSscr25               1.67            0.11          6
WTSscr7                1.63            0.11          6
WTS (PN4)              1.40            0.17          4
WTS (PN4 and PN6)      1.86            0.12          4
rd1 mice were treated (inontophoresis followed by intravitreal injec-
tion) at PN4, PN6, and PN8 (unless otherwise indicated) with a 500
µM of various oligonucleotides (ODNs). Other mice received no treat-
ment (None) or were treated with vehicle (PBS). WTS (PN4) are
data from mice treated only at PN4 (e.g., only one treatment total).
WTS (PN4 and PN6) are data from mice treated at PN4 and PN6
(e.g., only two treatments total). At PN28, retinas were harvested,
flat-mounted, and assayed for rhodopsin immunoreactivity using a
fluorescently labeled secondary antibody. Fluorescence was quanti-
fied by using the luminosity feature of Adobe Photoshop to normal-
ize the average brightness level per pixel of the tissue region to that
of the background region in each flat-mount image. Data are mean
of normalized fluorescence ±standard deviation. Sampling was num-
ber of retinas per group. Three separate treatments with WTS pro-
duced rhodopsin immunoreactivity significantly greater than other
treatments (*p<0.001 by simple analysis of variance (ANOVA) with
Student-Newman-Keuls post-hoc testing). All other treatments were
statistically indistinguishable from PBS treatment (p>0.05).
further processing. For immunohistochemical analysis, eyes
were dehydrated through a graded series of alcohol and xy-
lene then embedded in paraffin wax using a Histocentre 2
embedding center (Thermo Shandon, Waltham, MA). Sections
(5 µm) bisecting the optic disc superiorly to inferiorly were
cut on an American Optical/Spencer microtome (Buffalo, NY)
and fixed to glass slides.
Paraffin-embedded retina sections were deparaffinized,
permeabilized in 0.1%Triton X-100/PBS, blocked with 10%
normal goat serum in SuperBlock Buffer in PBS with 0.05%
Tween-20 added for 30 min, incubated with one of two pri-
mary antibodies specific to rhodopsin (1D4 or 4D2, gifts of
Dr. Robert Molday [40,44]; 1 µg/ml) for 1 h, then incubated
with Oregon Green-conjugated goat anti-rabbit IgG (1:1000
dilution; Molecular Probes, Eugene, OR, USA), and counter-
stained with propidium iodide (Molecular Probes), a drop of
SlowFade Light antifade medium was put on the section and
a cover slip placed on the slide. Sections were then observed
and photographed by computer-aided confocal microscopy
(Optiphot 2 microscope, Nikon Corporation, Melville, NY;
Bio-Rad MRC 1024 using filters 585 EFLP (for PI) and 522
DF32 (for fluorescein (488)), argon-krypton laser, running
LaserSharp 2000 version 5.2 build 824, Bio-Rad, Hercules,
CA). Images of individual fields were combined to produce
images of entire retinal sections using Adobe Photoshop CS
(version 8.0, Adobe Systems, Inc.). Cells of the ONL that
stained positive for rhodopsin immunoreactivity were counted
using Image Tool (UTHSCSA, San Antonio, Texas).
One to three sections were assessed for each eye.
Immunopositive cells in the ONL of each image were counted
by three observers who were unaware of the experimental
group from which the image originated. Observers’ counts were
averaged for each section. Some sections were missing seg-
ments of tissue due to preparation problems (e.g., microtome
blade chatter). This loss could artificially lower
immunopositive cells counts. To compensate for such artifacts,
the length of tissue from which counts were actually derived
was measured. The immunopositive cell count mean was di-
vided by this length and the result was used as the sample
value for that particular section. Group data are reported as
mean immunopositive cell number/cm tissue length ±SEM.
An unpaired Student’s t-test was used to compare means
of rd1S- versus WTS-treated groups in experiments in which
both eyes of a mouse were treated with the same ODN. In
experiments in which each mouse received WTS in one eye
and rd1S in the other eye, mean differences between treat-
ment groups were assessed using a paired Student’s t-test.
RESULTS
Delivery of oligonucleotides into retinal cells:
Transpalpebral iontophoresis was performed on PN7 mice
using an hour-glass-shaped electrode made with aluminum foil
and surgical sponge (Figure 1A) and connected to a power
supply (Figure 1B). Iontophoresis did not cause any detect-
able gross or histologic lesions to mouse eyes (Figure 1D and
[38]). When CY3-labeled WTS ODN was intravitreally in-
jected, but no inotophoresis was performed, fluorescence was
observed in the ganglion cell layer (GCL) and in a few cells
within the inner nuclear layer (INL) but not in the ONL (Fig-
ure 1E). In contrast, when PBS iontophoresis was applied
immediately prior to the ODN injection, intense fluorescence
was observed both in nuclei of the INL and the ONL (Figure
1F). No fluorescence was observed in any retinal layers of
PBS-treated eyes (Figure 1G) or uninjected control eyes (with
or without iontophoresis; data not shown; 8 eyes for each con-
dition).
Independent, confirmatory experiments similarly showed
ODN delivery to all retinal neural layers. No difference was
observed between iontophoresis being given before or after
intravitreal injection of fluorescently-labeled ODN, similar to
results previously published [38] (data not shown).
Outer nuclear layer nuclei numbers at PN28 are preserved
following treatment specifically with wild type oligonucle-
otides:  At PN4, PN6, and PN8, rd1 mice received iontophore-
sis then were intravitreally injected with PBS vehicle-only or
the various ODNs (1 µl of 500 µM solution). At PN28, mice
were sacrificed, eye enucleated, retina sections prepared, and
nuclei of the ONL counted. While a single row or less of sparse
cells was observed at PN28 in the ONL of untreated rd1 retina
(Figure 2A), discontinuous areas containing two or three rows
of nuclei were observed over the ONL of mice treated with
WTAS ODN and WTS ODN. Figure 2C,D represent two of
those areas where maximal rescue was observed. In PBS-
treated eyes, a smaller increase was observed in the ONL (Fig-
ure 2B).
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Quantification of these observations shows that treatment
with wild type ODNs resulted in the preservation nuclei in the
ONL. ONL cell counts following treatment with either WTAS
(101±15, mean±SD, on a 400 mm length; 8 eyes) or WTS
(103±14; 8 eyes) were significantly increased compared to
the number from PBS-treated retinas (74±5; 6 eyes) or un-
treated retinas from rd1 mice (55±8; 6 eyes; p<0.01; simple
ANOVA with Student-Newman-Kuels post-hoc testing). The
number of nuclei in the ONL was not significantly different in
retinas treated with WTAS versus WTS (p>0.05). The num-
ber of nuclei in the ONL was not significantly different in
untreated retinas versus PBS-treated retinas (p>0.05).
Rhodopsin immunostaining at PN28 is increased follow-
ing treatment specifically with wild type oligonucleotides:
Rhodopsin is the most abundantly-expressed photoreceptor-
specific protein and is frequently used as a marker to detect
the existence of rod photoreceptor cells [45-47]. To evaluate
the potential of ODNs to induce gene correction and subse-
quent photoreceptor survival, rhodopsin immunohistochem-
istry was performed on retina preparations from treated rd1
retinas at PN28. As in previous experiments, rd1 mice were
subjected to iontophoresis followed by injection with 1 µl of
500 µM WTS ODN at PN4, PN6, and PN8, with subsequent
sacrifice and tissue preparation at PN28. Wild type tissue was
examined at PN19 and PN28.
Extensive positive immunoreactive signal for rhodopsin
was observed in wild type eye sections at PN28 (Figure 3A).
Sections reacted with normal mouse serum in place of rho-
4D2 yielded no signal over background (Figure 3B). In rd1
flat-mount retinas, rhodopsin-positive signal was observed at
PN19 (Figure 3C), consistent with incomplete retinal degen-
eration at this age. The intense fluorescence observed at low
magnification at PN19 corresponded to dispersed immunore-
active photoreceptors as shown at a higher magnification (in-
set in Figure 3C). No positive signal was detected when nor-
mal mouse serum was used as control on rd1 flat-mount reti-
nas at PN19 (Figure 3D). At PN28, the rhodopsin signal was
extremely low, reflecting the advanced and nearly complete
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Figure 4. Responsiveness of rhodopsin immunoreactivity to the number of oligonucleotide treatments.  A: Three treatments with PBS (PN4,
PN6, and PN8). B: One treatment with ODN at PN4. C: Two treatments with ODN (PN4 and PN6). D: Three treatments with ODN (PN4,
PN6, and PN8). Scale bars : A, B, C, and D, 1 mm.
Figure 5. Rhodopsin immunohistochemistry on eye sections from PBS- or oligonucleotide-treated rd1 mice at PN28.  A: DAPI staining in blue
and rho-4D2 immunostaining in green (arrows) on section from PN28 PBS-treated rd1 retina. B: DAPI staining in blue and rho-4D2
immunostaining in green (arrows) on section from PN28 ODN-treated rd1 retina. Scale bars are A and B, 150 µm.
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Figure 6. Effect of treatment with WTS versus rd1S at PN33: A confirmatory experiment.  In experiments conducted with an independent
C3H/henJ colony, littermates treated with WTS ODN had many more rhodopsin-immunopositive cells in the ONL than littermates treated
with rd1S, the identical ODN with the exception of having the mutant rd1 nucleotide at the rd1 mutation site. Tissue was harvested and
sections prepared at PN33. A: Fluorescent micrographs of retina sections from rd1S-treated mouse (left panel) and WTS-treated mouse (right
panel). Rhodopsin immunosignal is green, counterstained nuclei are red. B: Composite image of confocal micrographs of retina section from
mouse treated with rd1S. Rhodopsin immunosignal is green, counterstained nuclei are red. Very little rhodopsin signal is apparent. Insets are
control sections in which no antibody was used or secondary antibody was used by normal rabbit sera (NRS) was substituted for primary
antibody. C: Composite image of confocal micrographs of retina section from mouse treated with WTS. Many rhodopsin-positive cells are
apparent in the putative photoreceptor layer. Insets are as in B. Quantification of rhodopsin-positive cells in photoreceptor layers showed that
significantly more signal was observed with WTS treatment compared to rd1S treatment (see “Results”).
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degeneration of rods in rd1 retinas at this time point (Figure
3E), paralleling the well-established time course of the rd1
retinal degeneration [45-47].
Conversely, as quantified in Table 2 and exemplified in
Figure 3F, treatment with WTS ODN yielded rhodopsin
immunostaining that was more intense compared to no treat-
ment, treatment with PBS alone, or treatment with either of
the negative control ODNs containing sequence mismatches
(WTSscr25, and WTSscr7). Further, treatment with negative
control ODNs did not induce significant increases in rhodop-
sin immunostaining compared to PBS treatment (Figure 3I
and Table 2), demonstrating the specificity of the response to
the combined iontophoresis/injection treatment with WTS
ODN. When WTS ODN injection was not coupled to the ap-
plication of current (Figure 3G) or when the current was ap-
plied without any intravitreal injection (Figure 3H), no effect
on rhodopsin immunostaining was observed.
While one single iontophoresis/injection treatment with
WTS at PN4 had no effect on photoreceptor survival, two treat-
ments at PN4 and PN6 induced a detectable, though not sta-
tistically significant, increase of rhodopsin immunostaining
(Table 2, Figure 4). Photoreceptor survival, as evaluated by
rhodopsin immunostaining on whole flat-mount retinas, was
significantly increased by three successive treatments with 1
µl of the 500 µM WTS ODN. Performing treatments at PN6,
PN8, and PN10 provided a rescue similar to that observed
when treatments were delivered at PN4, PN6, and PN8 (data
not shown).
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Figure 7. β-PDE immunohistochemistry and western blot.  A: Wild type +/+ eye section from a mouse at PN28. B: Control wild type +/+ eye
section from a mouse at PN28 using normal rabbit sera. C: Confocal micrograph from a C57/BL6 (wild type; +/+) retina reacted with β-PDE
primary antibody and Oregon Green-conjugated goat anti-rabbit IgG (giving green signal in figure) and counter-stained with propidium iodide
(giving red signal in figure). D: Confocal micrograph from wild type retina reacted with normal rabbit serum. E: Confocal micrograph from a
C3H/henJ mouse (rd1; -/-) retina reacted with β-PDE primary antibody and Oregon green-conjugated goat anti-rabbit IgG. OS indicates outer
segments, ONL indicates outer nuclear layer, INL indicates inner nuclear layer, GCL indicates ganglion cell layer. F: Anti-β-PDE “western”
immunoblot. Lane 1 is the molecular weight marker (sizes given on left), lane 2 is the polypeptide antigen against which the antibody was
raised, lane 3 is protein from a C3H (rd1) mouse retina, lane 4 is protein from a rd10 mouse retina, lane 5 is protein from an FVB (rd1) mouse
retina, lane 6 is protein from a CCRC (wild type +/+) mouse retina, lane 7 is protein from a Balb/C (wild type +/+) mouse retina. All mice were
at least 30 days old at time of tissue harvest. Scale bars are A, and B, 100 µm. These data suggest that the antibodies are highly specific and
selective to β-PDE.
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The application of three successive treatments (ionto-
phoresis prior to injection) at PN4, PN6, and PN8 with 1 µl of
500 µM WTS ODN had a significant effect on rhodopsin ex-
pression in PN28 rd1 mice, indicating increased photorecep-
tor survival. These conditions were used for all further experi-
ments.
Rhodopsin immunostaining on eye sections at PN28:
Clusters of rhodopsin positive cells in multiple rows were
detected across the retinas of mice treated with WTS ODN
(Figure 5B), while some cells in a single row of the residual
ONL were labeled in PBS-treated eyes (Figure 5A), demon-
strating that treatment by iontophoresis followed by injection
of specific ODNs induced the survival of rod photoreceptors
at PN28.
Rhodopsin immunostaining on eye sections at PN33: Con-
firmatory experiments:  In experiments conducted with an in-
dependent C3H/henJ (rd1) colony, littermates treated with
WTS ODN had more rhodopsin-immunopositive cells in the
ONL than littermates treated with rd1S, the identical ODN
with the exception of having the mutant rd1 nucleotide at the
rd1 mutation site. This effect was observed with either 4D2
(Figure 6A) or 1D4 rhodopsin antibodies (Figure 6B,C). Quan-
tification of the data obtained with 1D4 antibody showed that
this difference was statistically significant (WTS-treated:
97±12, N=11; rd1S-treated: 53±15, N=6. p=0.0438 by
Student’s unpaired t-test). In experiments in which one eye of
a littermate was treated with rd1S and the other eye was treated
with WTS, such that each mouse was its own control, treat-
ment with WTS again resulted in more rhodopsin-
immunopositive cells than treatment with rd1S (45 ±6.4 ver-
sus 26 ±11, respectively, four mice per group. p=0.0454 by
Student’s paired t-test).
Detection of β-PDE immunoreactivity in retina sections
at PN28:  An antibody directed against β-PDE specifically
labeled rod outer segments in the wild type mice at PN28 (Fig-
ure 7A-E). The specificity of the anti-β-PDE antibody was
confirmed by immunobloting with a specific signal on wild
type retinas and an absence of signal on rd1 retinas at ap-
proximately 88-90 kDa (Figure 7F). Some immunoreactivity
is observed at about 60 kDa in C3H rd1 and rd10 mice. (rd10
mice do not express β-PDE in adulthood [41].)
In the rd1 mouse without ODN treatment, β-PDE immu-
noreactivity was not present at any stage on retina sections.
However, in the 500 µM WTS ODN-treated rd1 eye sections,
a positive fluorescent signal for β-PDE was observed (Figure
8A). An average of 26±6 β-PDE immunopositive cells were
detected on whole sections from ODN-treated flat-mount retina
(3.5 mm long by 10 µm thick). The 3.5 mm by 10 µm section
corresponds to a surface area of 0.035 mm2, or 743 positive
cells per mm2. The estimated surface area of a retina is two-
thirds the surface of a sphere (4pr2), and for a radius of 1.25
mm at PN28, this is 13.1 mm2. The entire retina therefore has
roughly 743x13.1=9730 β-PDE positive cells. Double label-
ing with rho-4D2 showed that cells positive for β-PDE were
also positive for rhodopsin (Figure 8B). However, rhodopsin-
expressing cells were much more numerous than those ex-
pressing β-PDE (Figure 5B and Figure 8A). No significant
fluorescence due to β-PDE immunoreactivity was observed
when ODN was omitted in otherwise complete treatments (data
not shown).
Analysis of conversion of genomic DNA from rd1 to wild
type: DNA extracted from ODN- or PBS- treated rd1 retinas
and from wild type retinas was used as DNA template in al-
lele-specific real-time PCR with primers designed to amplify
only wild type DNA. The threshold cycle values (Ct) were
35±0.6 (6 retinas) for the ODN-treated group and 37±0.5 (5
retinas) for the negative control PBS group. The Ct for the
same amount of pure wild type genomic DNA was 26±0.1 (6
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Figure 8. Rhodopsin and β-PDE immunohistochemistry on eye sections from PBS- or WTS ODN-treated rd1 mice at PN28.  A: DAPI staining
in blue and β-PDE immunostaining in red (arrows) on section from PN28 ODN-treated rd1 retina. B: Combined fluorescence of β-PDE
immunostaining in red, rho-4D2 immunostaining in green and DAPI staining in blue on section from PN28 ODN-treated rd1 retina. Scale bars
are A, 150 µm; B, 10 µm. β-PDE immunoreactivity is associated with cells in the remaining outer nuclear layer (ONL). This staining appears
associated with the cytoplasm, not the nucleus. The rhodopsin immunoreactivity is associated with the same cells in the ONL and the immu-
noreactivity seems more peripheral to the cytosolic β-PDE staining, suggesting a plasma membrane localization of the rhodopsin immunore-
activity. Relatively few cells in the residual ONL exhibit either rhodopsin or β-PDE immunoreactivity at P28 even after three ODN treatments;
however, those remaining positive cells exhibit some degree of clustering.
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retinas; Figure 9). Treatment of the rd1 mice, as performed in
our study, leads to a significantly lower Ct compared to the
negative control PBS group (unpaired t-test; p=0.0334), indi-
cating that the ODN-treated group contained wild type DNA
and suggesting that treatment induced repair of genomic DNA
in rd1 mice. Based on the efficiency analysis, the effect of
treatment on the appearance of wild type β-PDE DNA copy
number was taken as 1.95(a-b) where a=Ct for ODN treatment
and b=Ct for wild type genomic DNA. The 1.95(a-b) value di-
vided into 100% provides the percent conversion of the mu-
tant adenine to wild type, i.e., 100/1.95(a-b)=100/1.95(35-
26)
=0.2%.
DISCUSSION
 Our results provide evidence that gene repair in photorecep-
tor cells is feasible when iontophoresis is combined with
intravitreal injection of a phosphorothioate single-stranded
ODN. β-PDE gene repair was detected in 0.2% of the genomic
DNA from treated rd1 retinas. Phenotypically, this repair was
demonstrated by the appearance of β-PDE immunoreactivity
and preservation of rhodopsin immunoreactivity in treated rd1
mice retinas at PN28, a stage when untreated or mock treated
mice do not express any β-PDE or significant rhodopsin. De-
spite the relatively low number of converted copies of genomic
DNA, a significant rescue of photoreceptors was observed.
These effects were not seen in eyes treated with buffer or with
ODNs having the rd1 mutant sequence, a definitive control
for this therapeutic approach. Further, critical experiments were
confirmed in two separate laboratories by several different
researchers using independent mouse colonies and ODN prepa-
rations from independent sources. The present work is a proof-
of-concept exercise that demonstrates the feasibility of this
non-viral, ODN-targeted gene repair strategy in the neural
retina.
For targeted gene repair, the delivery of a sufficient amount
of ODNs to the target cells is thought to be critical. In the eye,
direct intravitreal injection allowed little ODN to reach pho-
toreceptor nuclei. As shown by the distribution study (Figure
1), the application of iontophoresis prior to the injection of
ODNs results in an increased penetration of ODNs into pho-
toreceptor nuclei. Only repeated treatment induced a signifi-
cant preservation of photoreceptors. Therefore, in our study,
photoreceptor cell rescue required repeated delivery and a criti-
cal amount of intravitreal ODN combined with an enhanced
penetration efficiency to the target cells. Others studies have
shown that iontophoresis increases intracellular penetration
of small gene fragments [35-37]. It is surprising that, in the
present study, iontophoresis before intravitreal injection
worked as well as iontophoresis after injection. It is possible
that iontophoresis in our experiment was not critical for mov-
ing DNA, but instead iontophoresis may boost ODN trans-
port by current-induced changes of the plasma membrane or-
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Figure 9. Representative plots of allele specific real time polymerase chain reaction.  The graph shows the real-time detection of fluorescence
resulting from intercalation of SybrGreen fluorescent dye into double-stranded PCR products. Template DNA was isolated from BALB/c
mouse (WT), retinas of rd1 mice treated with WTS oligonucleotide (ODN-treated), or retinas of rd1 mice treated with PBS (PBS-treated).
Primers were specific for wild type allele. Each curve represents a different eye. Each experimental sample was assayed in 5-10 replicates. See
“Materials and Methods” for details of detection threshold calculation (orange horizontal line), normalization, and quantification. Control
experiments in which WT ODNs were doped into rd1 DNA show no shift to the left. Numerous experiments with rd1 DNAs isolated from
many different individual mouse eyes all showed the typical curve of the PBS-treated samples crossing threshold at about 37 cycles.
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ganization or changes in the structure and constituents of ex-
tracellular matrices [48]. In the skin, transport during post-
iontophoretic periods has been described [49], and the use of
saline iontophoresis prior to drug application was previously
shown to increase drug penetration [50]. Further experiments
will be needed to understand this phenomenon.
The type of ODN is another critical issue in gene repair.
In our model, the sense ODN (targeting the transcribed strand
of genomic DNA) and antisense ODN (targeting the non-tran-
scribed strand of genomic DNA) induced roughly equivalent
genomic repair. Several studies have shown that the stranded-
ness of ODNs influences their targeted repair efficacy
[9,23,51]. In a previously reported in vitro study, antisense
ODNs were found more effective than sense ODNs for induc-
ing gene repair [8]. However, the superior efficacy of the
antisense ODN is not universally observed; recent in vitro and
in vivo studies have found the sense ODN to be significantly
more effective [23,52-54]. Several factors such as transcrip-
tion activation, the phase of the cell cycle, and genomic se-
quences surrounding the target mutation may influence the
strand bias [54]. We have developed an in vitro model to study
the importance of the target DNA sequence in gene repair. It
is based on the introduction of different target sequences at a
single identical genomic site in 293T cells. Using this model,
we have demonstrated that strand bias is sequence specific.
Using this model, we demonstrated that antisense and sense
ODNs were roughly equivalent in targeting the sequence con-
taining the rd1 mutation [25]. Although this in vitro approach
was not conducted using retinal cells, it will be useful in as-
sessing what factors potentially influence the frequency of rd1
correction. The selection of optimized parameters will be ap-
plied in vivo to enhance the repair of the rd1 mutation.
The minor effect of PBS or scrambled ODN treatment on
photoreceptor survival as observed on flat-mount retinas
rhodopsin immunohistochemistry compared to untreated con-
trol (see Table 2) may be attributed to the induction of endog-
enous neurotrophic factors, known to delay retinal degenera-
tion in the rd1 mouse model [39,55,56]. Such an effect has
been detected in eyes following surgical interventions and other
forms of mock, sham, or vehicle control treatments [57-62]. A
neurotrophic effect may also explain the much larger number
of preserved rhodopsin-positive cells than β-PDE positive
cells. Thus, a strategy combining our therapeutic approach with
the additional use of neurotrophic factors may potentiate the
effect of genomic repair.
Our results are proof of concept. Although the incidence
of repair is low, the characteristics of the rd1 degeneration as
a model for human disease should be considered when weigh-
ing the potential of this approach. In the rd1 mouse, retinal
degeneration begins soon after birth and progresses quickly,
allowing only a narrow window of opportunity for effective
gene repair. Furthermore, in this mouse model, an extensive
and very rapid degenerative process results in a toxic environ-
ment for corrected cells. In humans, most of the degenerative
diseases apparently progress slowly, hypothetically allowing
a longer therapeutic window. At the present, other models of
slowly progressing retinal degeneration are being evaluated
in our laboratories. Using these models, we will be able to
determine whether applying a larger number of treatments will
increase targeted gene repair efficiency and whether gene re-
pair allows for a permanent rescue of photoreceptors.
In conclusion, this study provides a proof of principle for
non-viral targeted gene repair in photoreceptors of the rd1
mouse using a combination of iontophoresis and intraocular
injection of specific ODNs and opens new avenues for the
treatment of ocular degenerative and blinding eye diseases.
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